Firm intentionHealthcare16 November 2026

Merck KGaA, Darmstadt, Germany to acquire Rapid Micro Biosystems, Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Merck KGaA, Darmstadt, Germany
Target
Rapid Micro Biosystems, Inc.
Deal value
Not disclosed
Announced
16 November 2026
Status
Firm intention
Sector
Healthcare
Country
United States
Consideration
cash
What we know

Merck KGaA, Darmstadt, Germany has agreed to acquire Rapid Micro Biosystems, Inc. (Nasdaq: RPID) for cash. The Agreement and Plan of Merger was signed on November 16, 2026 with EMD Holdings NewCo II, Inc, a wholly owned Delaware subsidiary of Merck KGaA that will act as purchaser. Rapid Micro Biosystems disclosed the agreement the same day in a Form 8-K and said it issued a press release announcing it.

The purchaser will launch a cash tender offer for all Class A and Class B common stock at $0.75 per share, without interest and subject to tax withholding. The filing gives no aggregate deal value. The offer will initially expire one minute after 11:59 p.m. Eastern Time on the date 10 business days after it commences, and it can be extended in certain circumstances. As of the filing, the tender offer had not yet commenced.

The Company Board unanimously approved the agreement and recommended that stockholders tender their shares. Certain stockholders, including all board members and certain executive officers, who together beneficially own about 19.58% of the common stock signed Tender and Support Agreements committing them to tender. These agreements end on certain events, including a valid termination of the merger agreement. The Company agreed to no-shop restrictions with a fiduciary exception for unsolicited proposals that could lead to a superior proposal, and it owes Merck KGaA a $1,573,000 termination fee in specified circumstances, including a switch to a superior proposal or an adverse recommendation change.

Offer conditions include a majority minimum tender of Class A shares (counting Class A shares already held by Merck KGaA and its affiliates and including pre-funded warrant shares in the share count), accurate representations, covenant compliance, no continuing Material Adverse Effect, and no legal prohibition. After the offer is consummated, the purchaser will merge into the Company under Section 251(h) of the DGCL with no stockholder vote, leaving the Company as a wholly owned Merck KGaA subsidiary. Remaining shares convert into the $0.75 cash price, subject to appraisal rights. Vested options and RSUs are cashed out, unvested awards become cash-based awards on the original vesting schedule, and options with exercise prices at or above $0.75 are cancelled for no consideration. Warrants are treated by series: some are cashed out at the spread, the Series B warrants are purchased at Black Scholes value unless a holder elects otherwise under their terms, and the 2025 and 2018 warrants are cancelled without consideration.

Deal timeline

1 update
  1. Firm intention

    Merck KGaA, Darmstadt, Germany firm intention to acquire Rapid Micro Biosystems, Inc.

    Item 1.01. Entry into a Material Definitive Agreement. On November 16, 2026, Rapid Micro Biosystems, Inc., a Delaware corporation (the “ Company ”), Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“ Parent ”), and EMD Holdings NewCo II, Inc, a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”), entered into an Agreement and Plan of Merger (the

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

Merck KGaA, Darmstadt, Germany

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive